Power Dynamics Change As Pharma Downsizes
This article was originally published in The Pink Sheet Daily
Executive Summary
Shift increasingly favors smaller, more nimble biotechs in deals.
You may also be interested in...
Ernst & Young: “Optionality” Here To Stay, As Biotech Business Model Reinvents Itself
Chaos in the capital markets may force shortened R&D timelines that result in structured acquisitions, novel deal structures, and a boom in personalized medicine.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.